Astrazeneca Share News (AZN)

TOP NEWS: AstraZeneca ups guidance; inks licence deal for obesity drug

(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu.

LONDON MARKET OPEN: FTSE 100 kicks off day with cautious gain

(Alliance News) - London's FTSE 100 struggled for direction early Thursday, with a mixed slate of corporate updates, US interest rate worries and underwhelming China data preventing it from making more confident progress in early trade.

LONDON BRIEFING: AstraZeneca ups outlook but S4 Capital cuts

(Alliance News) - London's FTSE 100 is set for another downbeat start to the day, with more hawkish comments from US central bankers and tepid data out of China doing little to lift the mood.

AstraZeneca hikes guidance after strong third quarter

(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.

AstraZeneca plans next phase of trial on kidney drug combination data

(Alliance News) - AstraZeneca PLC on Friday touted results from a Phase IIb trial, which showed that a zibotentan and dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria.

AstraZeneca's Lokelma lets kidney disease patients maintain therapy

(Alliance News) - AstraZeneca PLC on Thursday celebrated results from an observational study, which showed that treating hyperkalaemia with the potassium binder, Lokelma, allows chronic kidney disease and heart failure patients to maintain RAASi therapy.

UK earnings, trading statements calendar - next 7 days

AstraZeneca launches collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Wednesday announced a new collaboration and investment agreement with clinical-stage biotechnology company Cellectis.

AstraZeneca invests $220m in French gene-editing group Cellectis

(Sharecast News) - AstraZeneca is to invest in French biopharma group Cellectis to use its gene-editing technologies to develop next-gen therapeutics in areas like oncology, immunology and rare diseases.

LONDON BROKER RATINGS: Jefferies cuts NatWest to underperform from buy

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

PRESS: Soriot commits to five more years as AstraZeneca CEO - Times

(Alliance News) - Pascal Soriot has committed to remaining as chief executive officer of AstraZeneca PLC for another five years, The Times reported on Wednesday.

LONDON MARKET CLOSE: FTSE 100 shakes off midday losses after US data

(Alliance News) - The FTSE 100 closed in the green on Tuesday following positive private sector data out of the US, despite figures closer to home showing a weaker UK private sector and rising unemployment.

AstraZeneca says US accepts self-administered flu vaccine for review

(Alliance News) - AstraZeneca PLC on Tuesday said the US health watchdog has approved a review for its FluMist Quadrivalent self-administered flu vaccine, for which the drugmaker is seeking a green light.

AstraZeneca celebrates drug trial results for cancer indications

(Alliance News) - AstraZeneca PLC on Monday said new drugs, developed in partnership with Daiichi Sankyo Co Ltd, showed positive results in patients with solid tumours, lung and breast cancer.

LONDON MARKET CLOSE: Stocks largely down on Middle East hostilities

(Alliance News) - Stock prices in London closed largely lower on Monday, as investors were unable to shake off concerns surrounding the conflict in the Middle East, while developments in the US bond market added to the drama.